Biotech

All Articles

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was actually wowed enough with Port BioMed's bispecific immune reactor that i...

A closer look at Intense Biotech's Ferocious 15

.In this full week's incident of "The Top Pipe," our company're diving right into Tough Biotech's an...

Lilly experiences period 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's gathering celebrating the approval of Alzheimer's co...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of significant leadership hirings, shootings...

Lykos will certainly ask FDA to reexamine its decision observing rejection of MDMA therapy for post-traumatic stress disorder

.Complying with a bad presenting for Lykos Therapeutics' MDMA candidate for trauma at a latest FDA c...

AN 2 one-halfs roll call, quits period 3 trial after information disappoint

.AN2 Therapeutics is reviewing its own organization in response to uninspired midphase data, swearin...

Merck spends $700M for bispecific, snooping autoimmune position as well as opportunity to test Amgen in cancer

.Merck &amp Co. is actually paying out $700 million ahead of time to test Amgen in a blood stream ca...

Gilead pays for J&ampJ $320M to leave licensing deal for seladelpar

.Along With Gilead Sciences on the verge of an FDA choice for its liver health condition medication ...

' All hands on deck' at Lilly as peers target obesity market

.CEO David Ricks can easily view the companies putting together tents at basecamp behind Eli Lilly i...

Entero laying off workers, abandoning office and pausing R&ampD

.Bed Liquidators has turned Entero Rehabs white colored as a piece. The financial institution got En...